COPD by Doney, Brent et al.
Prevalence of Airflow Obstruction in U.S. Adults Aged 40–79 
Years: NHANES Data 1988–1994 and 2007–2010
Brent Doney1, Eva Hnizdo1, Charles F. Dillon2, Ryne Paulose-Ram2, Timothy Tilert2, 
Michael Wolz3, and Lu-Ann Beeckman-Wagner1
1Division of Repiratory Disease Studies, National Institute for Occupational Safety and Health, 
Centers for Disease Control and Prevention, Morgantown, WV, USA
2Division of Health and Nutrition Examination Surveys, National Center for Health Statistics, 
Centers for Disease Control and Prevention, Hyattsville, MD, USA
3National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
Abstract
Background—The study evaluated the change in the prevalence of airflow obstruction in the 
U.S. population 40–79 years of age from years 1988–1994 to 2007–2010.
Methods—Spirometry data from two representative samples of the U.S. population, the National 
Health and Nutrition Examination Surveys (NHANES) conducted in 1988–1994 and 2007–2010, 
were used. The American Thoracic Society/European Respiratory Society (ATS/ERS) criteria 
were used to define airflow obstruction.
Results—Based on ATS/ERS criteria, the overall age-adjusted prevalence of airflow obstruction 
among adults aged 40–79 years decreased from 16.6% to 14.5% (p < 0.05). Significant decreases 
were observed for the older age category 60–69 years (20.2% vs. 15.4%; p < 0.01), for males 
(19.0% vs. 15.4%; p < 0.01), and for Mexican American adults (12.7% vs. 8.4%; p < 0.001). The 
prevalence of moderate and more severe airflow obstruction decreased also (6.4% vs. 4.4%; p < 
0.01). Based on ATS/ERS criteria, during 2007–2010, an estimated 18.3 million U.S. adults 40–79 
years had airflow obstruction, 5.6 million had moderate or severe airflow obstruction and 1.4 
million had severe airflow obstruction.
Conclusions—The overall age-adjusted prevalence of airflow obstruction among U.S. adults 
aged 40–79 years decreased from 1988–1994 to 2007–2010, especially among older adults, 
Mexican Americans, and males.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and 
mortality worldwide (1). In the United States, an estimated 15 million people had doctor-
diagnosed COPD in 2010 and 12 million had undiagnosed COPD. COPD ranks third in 
causes of mortality resulting in about 100,000 deaths annually (2–4). COPD is a costly 
disease; direct and indirect healthcare costs are higher among COPD patients when 
compared to other patients. In a case-control study, COPD patients used 50–60% more 
medical services (inpatient, emergency department and office visits) than controls (5). The 
National Heart, Lung, and Blood Institute estimated the total annual cost of COPD for 2010 
to be $49.9 billion (6). COPD associated disability also reduces the probability of being 
employed by 8.6% (3). Despite the decreased prevalence of smoking over the last several 
decades (7, 8), a recent study reported that there was little change in the overall prevalence 
of COPD among 20–79 year olds between the periods 1988–1994 and 2007–2010 based on 
the NHANES pre-bronchodilator (pre-BD) spirometry data and using mainly the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (9) to define COPD (10).
Spirometry measurements of the forced expiratory volume in the first second (FEV1) and the 
FEV1 to forced vital capacity (FVC) ratio are recommended for the diagnosis of COPD and 
for the study of COPD prevalence (11). The interpretation of the ratio differs, however, 
depending on what professional recommendations are used. The American Thoracic 
Society/European Respiratory Society (ATS/ERS) recommends that a FEV1/FVC ratio 
below the lower 5th percentile (the lower limit of normal, or LLN) as determined from a 
representative sample of healthy non-smokers, be used to define airflow obstruction (12). 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) (9, 13) recommends 
that post-bronchodilator (post-BD) spirometry with a ratio of FEV1/FVC below 0.7 be used 
to identify COPD (14). Several studies have shown that the GOLD criteria can potentially 
over-diagnose COPD and over-estimate the COPD burden in older adults, especially if pre-
BD spirometry is used for the determination (15–18). Since COPD is a costly disease, it is 
important to ensure that the estimates of the COPD prevalence and burden in the current 
U.S. population are consistent and reliable to assure sufficient planning and funding for 
prevention, treatment, and research.
The aims of our study were as follows: 1) to evaluate changes in the prevalence of airflow 
obstruction among older adults (40–79 years) for two periods of the NHANES study 1988–
1994 and 2007–2010 focusing on the ATS/ERS criteria to define airflow obstruction (in 
contrast to the Ford et al. study (10)); 2) to evaluate the change in the COPD GOLD Stage 1 
status when using pre-BD and post-BD spirometry in the NHANES participants who had 
both tests; and 3) to test how well the NHANES III (1988–1994) reference equations (19) 
for spirometry fit the 2007–2010 data for healthy nonsmokers in order to assess reliability of 
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the estimates (NHANES III equations were applied to both samples to determine the 
presence of airflow obstruction).
Methods
The National Center for Health Statistics of the Centers for Disease Control and Prevention 
conducts the NHANES, which is a cross-sectional survey of the civilian, non-
institutionalized U.S. population (20). Household interviews and standardized physical 
examinations [in mobile exam centers (MEC)] are used to collect data. The NHANES 
survey samples are selected through a complex, multistage, probability design. The 
NHANES 2007–2010 survey cycles oversampled major U.S. demographic subgroups and 
the study procedures are detailed in the references (21, 22). Informed consent was obtained 
from all participants and the National Center for Health Statistics Research Ethics Review 
Board approved the protocol.
This study analyzed publicly available NHANES 1988–1994 and 2007–2010 spirometry 
data. During 1988–1994, 8495 persons aged 40–79 years were examined (79% unweighted 
response rate). Of these, 7667 (90%) had valid spirometry [the spirometry test met 
reliability/reproducibility quality control check (spprelia=1) and there were two or more 
successful maneuvers (sppmaneu>1)] and height data, and were used in our study. During 
2007–2010, 7104 persons aged 40–79 years attended the MEC exam (71% unweighted 
response rate) and were eligible for spirometry. 1281 participants were excluded from 
spirometry for various reasons [safety reasons (649), limited time available in the MEC 
(337), subject refusals (113), or other reasons (182)], and 346 had invalid spirometry tests or 
missing height information (1). Of those examined, 5476 (77%) had valid spirometry data 
and were included in our study.
Spirometry
NHANES 2007–2010 spirometry testing was performed in accordance with 
recommendations of the ATS (23) using Ohio 822/827 dry-rolling seal volume spirometers 
with biological filters (A-M Systems PFT Filter Kit B) to minimize infection risks. These 
were the same spirometers that were used in the NHANES III (1988–1994) study. The 
spirometry methods were similar for both surveys except for the following: 1) The 
spirometry software displayed both the volume-time and flow-volume curves in 2007–2010; 
only the flow-volume curve was displayed in 1988–1994, 2) NHANES III did not use in-line 
filters, 3) the minimum number of maneuvers performed per test session was three for 
NHANES 2007–2010 and five for NHANES 1988–1994, and 4) the 2007–2010 survey 
included annual refresher training and bi-weekly, as opposed to monthly, quality control 
reports by the National Institute for Occupational Safety and Health (NIOSH). In both 
studies, height was measured with a stadiometer.
In the 2007–2010 survey, participants whose test results indicated airflow obstruction 
(FEV1/FVC <LLN or FEV1/FVC <0.7) were selected for post-BD spirometry. Of the 1137 
(20.8%) selected 40–79-year old adults, because of time constraints or safety reasons, only 
577 (50.7%) had the post-BD test done. Since a previous study used the GOLD criteria to 
define COPD and pre-BD spirometry as opposed to the recommended post-BD spirometry 
Doney et al. Page 3













(10), we evaluated the potential bias due to using pre-BD tests in the estimation of COPD 
prevalence. For this purpose, we used the 577 participants with both the pre-BD and post-
BD spirometry in NHANES 2007–2010.
Airflow obstruction definitions—Using the ATS/ERS criteria, mild or more severe 
airflow obstruction (Mild+) was defined as the ratio of FEV1 to FVC below the lower 5th 
percentile (i.e., LLN) (12) and moderate or more severe airflow obstruction (Moderate+) 
was defined as FEV1/FVC <LLN plus FEV1 <70% predicted. We used modified GOLD 
Stage 1 criteria, where mild or or more severe (Mild+) airflow obstruction was defined as 
pre-BD FEV1/FVC <0.7 (13) and moderate or more severe (Moderate+) COPD was defined 
as pre-BD FEV1/FVC <0.7 plus FEV1 <80% predicted. Severe airflow obstruction was 
defined as for moderate, but using FEV1 <50% predicted, for both ATS/ERS and GOLD. 
U.S. population reference equations developed from NHANES III data were used to derive 
the predicted and LLN values for both periods (19). Reference values are available for non-
Hispanic white, non-Hispanic black, and Mexican Americans. In this study, for the “other” 
race category, we applied a correction factor of 0.88 to the reference values for FEV1 and 
FVC for non-Hispanic whites (24). For the “other Hispanic” group, we applied the reference 
values for Mexican Americans.
Demographic variables used in the analysis for both time periods included gender, self-
reported age, self-reported race/ethnicity including non-Hispanic (NH) white, NH black, and 
Mexican American, and self-reported education. Potential risk factors included self-reported 
smoking status (never, former, and current smokers), pack-years, and body mass index (kg/
m2).
To evaluate how well the NHANES III reference equations fit the NHANES 2007–2010 
spirometry data, we selected all “healthy” nonsmokers aged 20–79 years from the NHANES 
2007–2010 data and evaluated the the difference between the observed and predicted values 
derived from the NHANES III equations. We defined healthy nonsmokers as adults who 
were never smokers who reported no respiratory symptoms of chronic bronchitis, wheezing, 
or health care provider diagnosed respiratory disease (e.g., emphysema or chronic 
bronchitis) (19).
Data analysis
Prevalence estimates were computed using SAS, version 9.2 software procedure Proc 
SurveyReg (SAS Institute Inc. Cary, NC) (25). This procedure allowed us to account for the 
complex survey design (20) and to apply the NHANES examination weights assigned to 
each individual. To make estimates between the two time periods comparable with respect to 
the population age distribution, estimates were age adjusted by the direct method using the 
year 2000 Census Bureau projections for the U.S. civilian, non-institutionalized population 
with the following age groups: 40–49, 50–59, 60–69 and 70–79 (21, 26). The weighted 
frequencies and means were derived using SAS procedures Proc SurveyFreq and Proc 
SurveyMeans; both procedures accounted for the complex survey design and examination 
weights. To compare the prevalence estimates from NHANES 1988–1994 and 2007–2010, 
we used the t-test and the Bonferroni adjustment of the p values to account for multiple 
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comparisons within each categorical variable. To estimate the burden of COPD for the U.S. 
population, the average U.S. population size for years 2007–2010 was estimated using the 
national Current Population Survey (27) population size tables.
To investigate the suitability of the NHANES III based reference equations for the 2007–
2010 data, we fit the NHANES III reference equations to a group of “healthy-nonsmokers” 
20–79 as defined above. For each person we calculated the predicted values for FEV1, FVC, 
and the FEV1/FVC ratio based on the person’s ethnicity, age, height, and gender using the 
NHANES III reference equations. Next, we calculated the standardized differences between 
the observed and predicted values [i.e., z-score=(observed-predicted)/residual standard 
deviation]. The mean z-score and the lower 95% confidence limit were then plotted against 
categorized age, for adults 20 to 79 years of age and a t-test was used to test whether the 
mean z-score values differed significantly from zero.
To evaluate the differences in the percentage of those with COPD defined by GOLD Stage 1 
criteria using pre-BD spirometry and post-BD spirometry, we used the data for those 
participants who had post-BD spirometry and calculated the unweighted percentage with 
COPD for pre-BD spirometry and post-BD spirometry.
We also evaluated the differences between the prevalences of airflow obstruction defined by 
the GOLD Stage 1 and 2 and the ATS/ERS criteria, for the 2007–2010 time period.
Results
Table 1 provides the descriptive statistics for the NHANES 1988–1994 and 2007–2010 
participants aged 40–79 with valid spirometry and height, n =7667 and n =5476, 
respectively. The two study samples were similar with respect to mean age (55.4 vs. 54.9 
years; p >0.05) (data not shown) and gender distribution (p >0.05). The 2007–2010 sample 
population had, however, a higher level of education, where 47.6% had at least some college 
education or higher vs. 27.2% in 1988–1994 (p <0.001). Also, the NHANES 2007–2010 
sample had a higher proportion of never-smokers (49.6% vs. 42.6%; p <0.001) and the 
combined categories of former smokers and current smokers showed a decrease in mean 
pack-years of smoking (23.3 vs. 29.1; p <0.001). The prevalence of obesity (body mass 
index (BMI) of 35 kg/m2 or greater) increased in 2007–2010 (16.9% vs. 10.0%; p <0.001).
Table 2 shows the age-standardized prevalence of Mild+airflow obstruction by ATS criteria 
(FEV1/FVC <LLN) for the 40–79 year olds. The overall prevalence decreased from 16.6% 
(SE 0.8) during 1988–1994 to 14.5% (SE 0.7) during 2007–2010. The decrease in 
prevalence between 1988–1994 and 2007–2010 also reached statistical significance for 60–
69 years old, males, and Mexican-American adults.
The age-standardized prevalence of Moderate+airflow obstruction defined as FEV1/FVC 
<LLN and FEV1 <70% predicted is also seen in Table 2. The overall prevalence dropped 
from 6.4% (SE 0.5) during 1988–1994 to 4.4% (SE 0.4) during 2007–2010. Again, the 
2007–2010 prevalence was lower, reaching statistical significance for the 60–69 year age 
group, both genders, NH white and Mexican American persons, and those with some college 
education.
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Further, Table 2 includes the the age-standardized prevalence for severe airflow obstruction 
based on the ATS/ERS criteria, for 40–79 year olds. The overall prevalence was 2.2% (SE 
0.2) for years 1988–1994 and 1.1% (SE 0.2) for 2007–2010. There was significant decline in 
the prevalence of severe airflow obstruction for adults 60–69 years, both genders, NH white 
adults, and those with some college education. There was also a decline among current 
smokers (p <0.05). Often, the prevalence for the years 2007–2010 was about half of the 
prevalence for 1988–1994 for the demographic factors.
Figure 1 shows the prevalence of airflow obstruction (ATS/ERS and modified GOLD 
criteria) by age categories and time period. Table 3 shows the statistical differences between 
the estimates of prevalence of airflow obstruction based on ATS/ERS and GOLD Stage 1 
and 2 criteria, for NHANES 2007–2010. The prevalence of ATS/ERS Mild+airflow 
obstruction overall, and age, gender, race, education and smoking status-specific prevalence 
were all significantly lower, with the exception of the 40–49 years olds. For that 40–49 age 
category, the prevalence of airflow obstruction was less for GOLD than for ATS/ERS which 
is consistent with the GOLD underestimation in the younger age categories. For Moderate
+airflow obstruction, ATS/ERS was consistently significantly less than GOLD for all 
categories.
Using the average U.S. population size for 40–79 year olds for years 2007–2010 of 
126,199,000 and prevalence of ATS/ERS defined airflow obstruction of 14.5% for Mild+, 
4.4% for Moderate+, and 1.1% for severe degree, we estimated the number of individuals in 
the United States. with COPD. The burden of COPD is approximately 18.3 million with 
Mild+(95% CI 16.4–20.3), 5.6 million with Moderate+(95% CI 4.4–6.6) and 1.4 million 
with severe (95% CI 0.9–1.8).
Post-bronchodilator spirometry is required for the GOLD definition of COPD to determine 
reversibility of airflow obstruction (9). In the NHANES 2007–2010 study of the 5476 adults 
40–79 years of age with valid spirometry, 1137 (20.8%) were selected for BD follow-up 
because their spirometry results indicated the presence of airflow obstruction defined by the 
ATS/ERS or GOLD Stage 1 criteria (i.e., FEV1/FVC <LLN or FEV1/FVC <0.7). Of the 
1137 cases, only 577 (50.7%) had the bronchodilator test done. Of those with a post-BD test 
and pre-BD GOLD Stage 1 (549), only 354 (64.4%) remained in the GOLD Stage 1 
category after post-BD testing and 35.5% became “normal.” However, of the 560 who didn’t 
have the post-BD test, 315 were not tested because of safety reasons (such as uncontrolled 
blood pressure, irregular pulse on examination, taking medication for major arrhythmia or 
certain other medications, implanted defibrillator, or history of congenital heart disease) and 
245 were not tested for other reasons (refusal, insufficient time, and others). Exclusion of 
those for safety reasons may have potentially decreased the reversibility rate. However, 
based on nonparametric testing, there were no significant differences between the group that 
had post-BD test and the two groups that did not have the post-BD test for safety reasons or 
for other reasons for the percent predicted FEV1/FVC ratios on pre-BD spirometry.
To test how well the NHANES III reference values fit the NHANES 2007–2010 sample 
population, we selected all “healthy” non-smokers 20–79 years of age from the NHANES 
2007–2010 data (n =1980). The mean standardized differences between the observed and 
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predicted values (z-score) were as follows: for FEV1 0.047 (SE 0.02; t =2.1; p <0.05), for 
FVC 0.151 (SE 0.02; t =6.4; p <0.001), and for the FEV1/FVC ratio −0.188 (SE 0.02; t = 
−8.5; p <0.001). The t-test values indicate that the observed mean z-scores were significantly 
different from zero especially for FVC and the ratio. Figures 2–4 show the distribution of the 
z-scores, the mean z-scores and their lower 95th percentile, by age categories.
The mean z-scores were close to zero for FEV1 for most age categories, but consistently 
above zero for FVC. The higher z-score values for FVC reflect higher observed FVC values 
for the NHANES 2007–2010 sample than was predicted based on the NHANES III-based 
reference equations. The higher observed FVC values then result in the lower mean 
FEV1/FVC values for NHANES 2007–2010, in comparison to the predicted values derived 
from the NHANES III reference equations and thus a negative z-score. The mean z-scores 
[(Observed-Predicted)/Relative Standard Deviation] are negative for most of the age 
categories since predicted FEV1/FVC values based on the NHANES III data are higher than 
the observed mean FEV1/FVC values. Consequently, because the distribution of the 
observed FEV1/FVC values is shifted towards zero with respect to the predicted and LLN 
values, the LLN values derived from the NHANES III equations identified more than 5% as 
being abnormal. Of the healthy non-smokers from the NHANES 2007–2010 sample, on 
average 7.4% were identified as having FEV1/FVC<LLN.
Discussion
We analyzed NHANES spirometry data from time periods 1988–1994 and 2007–2010 to 
evaluate changes in the prevalence of airflow obstruction, a main feature of chronic 
obstructive pulmonary disease, among older adults (age 40–79). Our results show that the 
ATS/ERS-defined prevalence of airflow obstruction declined significantly from 16.6 to 
14.5% (p <0.05) for Mild+airflow obstruction and from 6.4 to 4.4% (p <0.01) for Moderate
+airflow obstruction. There was a statistically significant decline in the prevalence of airflow 
obstruction in the age category 60–69 from 20.2% to 15.4% (p <0.01). In addition, severe 
airflow obstruction declined significantly in current smokers. Reasons for the decline may 
include decrease in the prevalence of smoking in the U.S. population, and reductions in 
occupational exposures and air pollution since 1988–1994.
Although our study shows decline in the prevalence of airflow obstruction, COPD remains 
one of the leading causes of death in the U.S. (28). The high mortality rate from COPD may 
be explained by higher life expectancy and decreased early mortality from cardiovascular 
disease (28–31). Results from the National Health Interview Survey (NHIS) 2007–2009 
showed that the prevalence of COPD (self-reported doctor-diagnosed chronic bronchitis in 
the past year or ever emphysema) increased systematically with age from 5.7% for the 45–
54 year olds to 7.6% among those 55–64, and 9.5% for the 65–74 year old U.S. adults (32). 
This lower doctor-diagnosed NHIS estimates reflects different diagnostic methods other than 
spirometry results, i.e. symptoms of chronic bronchitis or shortness of breath in the doctor-
diagnosed COPD, medical diagnosis of COPD without pulmonary function testing (33), or 
differences in the survey methods. The lower prevalence of doctor-diagnosed disease may 
also indicate underdiagnosis of COPD in the U.S. population. Nevertheless, the observed 
declining trend in the prevalence of airflow obstruction based on spirometry measurements, 
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as observed in our study, is likely to be reflected in declining morbidity and mortality from 
COPD in the future if the trend in the decreasing exposure to particulates continues (34, 35).
A previous study by Ford et al. (10) reported no significant differences between NHANES 
III and NHANES 2007–2010 sample populations in the prevalence of COPD (overall 
prevalence 14.6% vs. 13.5%, p >0.05) for ages 20–79 years using GOLD Stage 1 and 2 
criteria and pre-BD spirometry. Ford et al. estimated the prevalence of airflow obstruction at 
29.4% in the 60–79-year age group. Ford et al. did not apply any reliability/reproducibility 
exclusion criteria to the NHANES III data while our NHANES III analysis was limited to 
those with reliable spirometry exams and at least 2 maneuvers, which may explain some of 
the differences with our study. Our results also show that the differences in the prevalence of 
GOLD Stage 1 and Stage 2 for the two time periods are not statistically significant, for the 
age categories (Figure 1). One of the reasons for the different findings by the two studies is 
that the GOLD Stage 1 and GOLD Stage 2 defined on pre-bronchodilator spirometry over-
estimate the disease prevalence. In this study, the GOLD defined prevalence of COPD was 
significantly higher than the prevalence of ATS/ERS defined airflow obstruction, for Mild
+and Moderate+categories, but not for the severe category (Table 3).
The burden of COPD was likely also overestimated by Ford et al. using the GOLD criteria 
based on the fixed ratio and using pre-BD spirometry. Ford et al. estimates that in the larger 
U.S. population 20–79 age group 28.9 million have mild or more severe airflow obstruction 
based on GOLD Stage 1, 12.9 million have moderate and more severe obstruction based on 
GOLD Stage 2, and 1.5 million have severe airflow obstruction based on GOLD Stage 3. 
For the U.S. population aged 40–79, we estimated that the burden of COPD based on the 
prevalence of ATS-defined airflow obstruction, the main feature of COPD, for the U.S. 
population 40–79 age group was approximately 18.3 (95% CI 16.4–20.3) million for Mild
+airflow obstruction, 5.6 (95% CI 4.4–6.6) million for Moderate+airflow obstruction, and 
1.4 (95% CI 0.9–1.8) million for severe airflow obstruction.
Our estimate for the 40–79 age group based on pre-BD criteria was approximately 25.2 
(95% CI 22.3–27.8) million for GOLD Stage 1 (Mild+), 11.4 (95% CI 9.7–12.9) million for 
GOLD Stage 2 (Moderate+), and 1.4 (95% CI 0.9–1.9) million for GOLD stage 3 (severe). 
Thus there are large differences in the estimated burden of COPD when using the GOLD 
and ATS-based estimates for Mild+obstruction (25.2 vs. 18.3 million ≈6.9 million) and for 
Moderate+obstruction (11.4 vs. 5.6 million ≈5.8 million) for the U.S. population aged 40–
79.
Many publications have reported that the usage of the fixed FEV1/FVC ratio criterion of 0.7, 
especially when using pre-BD spirometry, leads to over estimation of the COPD prevalence 
in older adults (15–18, 36, 37). The PLATINO study indicated that applying GOLD 1 
criteria to pre-BD spirometry, rather than post-BD spirometry as required by GOLD 
recommendations, may overestimate the COPD prevalence by approximately 35% (38). 
However, Tashkin et al. (39) reported substantial acute bronchodilator reversibility in 
patients with early COPD who had no other features of asthma suggesting that BD 
reversibility may not be a completely reliable way of distinguishing asthma and COPD.
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We have determined using the z-score analysis that usage of the NHANES III equations may 
potentially lead to a slight overestimation of the prevalence of airflow obstruction in the 
2007–2010 data. Although the reference equations fit well to the FEV1 data, FEV1 z-scores 
were around zero, z-scores for FVC (i.e., for both the predicted and LLN values were 
systematically above zero and above −1.645, respectively, for most age categories) and the 
mean z-score was significantly higher than zero. As expected, the resulting z-score values 
for the ratio of FEV1/FVC were lower than zero for the predicted value and below −1.645 
for the LLN values, and the mean z-score was significantly lower than zero. This may be due 
to better spirometry quality in the 2007–2010 testing period.
Consequently, more “healthy never smokers” from 2007–2010 population sample were 
classified with airflow obstruction using the NHANES III LLN criteria for the FEV1/FVC 
ratio (7.4%) rather than the expected 5%, potentially leading to overestimation of the 
prevalence of airflow obstruction (Figure 4). This, in turn, likely underestimates the true 
difference between the NHANES III and current NHANES estimates. This result indicates 
that a new set of reference equations may be needed for the current U.S. population. 
Applicability of the Global Lung Initiative 2012 reference equations (40) for the current 
U.S. population should be evaluated.
The results show reduction in the prevalence of airflow obstruction mainly in the 60+ages 
(Figure 1), and the decline was significant in the 60–69 age category. There are limitations, 
however, that need to be considered when interpreting these results. First, the exclusion 
criteria, the participation rate in the spirometry testing and the valid spirometry rate were 
different in the NHANES 2007–2010 study than in the NHANES III, resulting in lower 
overall rate in those with valid spirometry (90% vs. 77%). However, NHANES is a 
demographically based survey with a complex multistage design incorporating probability, 
stratified and cluster sampling at different stages.
The statistical software uses design variables (primary sampling units, strata) and non-
response adjusted sample weights to produce adjusted prevalence estimates. Secondly, the 
definition of airflow obstruction was based on NHANES III reference equations (19) and we 
have shown in this article that their usage may potentially lead to overestimation of the 
prevalence of airflow obstruction in NHANES 2007–2010. Generally, because of stringent 
spirometry review of the flow-volume curves, it is unlikely that participants with airflow 
obstruction would be excluded from these two studies due to invalid spirometry.
Conclusion
In conclusion, the prevalence of ATS/ERS-defined airflow obstruction decreased 
significantly from 1988–1994 (16.6%) to 2007–2010 (14.5%), p <0.05. We estimated, based 
on the prevalence of ATS/ERS-defined airflow obstruction, a main determinant of COPD, 
that approximately 18.3 million adults aged 40–79 have Mild+airflow obstruction, 5.6 
million have Moderate+airflow obstruction, and 1.4 million have severe airflow obstruction 
in the current U.S. population.
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Prevalence of airflow obstruction by severity, by age category, by time period. ATS/ERS 
Mild+: Mild or more severe airflow obstruction. ATS/ERS Moderate+: Moderate or more 
severe airflow obstruction. *Modified GOLD criteria. GOLD Stage 1: Mild or more severe 
airflow obstruction. GOLD Stage 2: Moderate or more severe airflow obstruction.
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Z-score for FEV1 by age; −1.645 line is the lower limit of normal – 5th percentile; Short 
dashed line connects the mean z-score for each age category in relation to zero; Long dashed 
line connects the mean LLN for each age category.
Doney et al. Page 14














Z-score for FVC by age; −1.645 line is the lower limit of normal – 5th percentile; Short 
dashed line connects the mean z-score for each age category in relation to zero; Long dashed 
line connects the mean LLN for each age category.
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Z-score for ratio by age; −1.645 line is the lower limit of normal – 5th percentile; Short 
dashed line connects the mean z-score for each age category in relation to zero; Long dashed 
line connects the mean LLN for each age category.
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